Expression of FK506 binding protein 65 (FKBP65) is decreased in epithelial ovarian cancer cells compared to benign tumor cells and to ovarian epithelium

Tumor Biology

Volumn 32, Issue 4, 2011, Pages 671-676

  Henriksen, Rudi ^a   Sørensen, Flemming Brandt ^b   Ørntoft, Torben Falck ^c   Birkenkamp Demtroder, Karin ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LILLEBAELT HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

FK506 binding protein 65; Immunohistochemistry; Ovarian cancer; Ovary; Rapamycin; Tacrolimus

Indexed keywords

FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 65; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; TUMOR CELL;

EID: 80052333239     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-011-0167-4     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Ashworth A, Balkwill F, Bast RC, Berek JS, Kaye A, Boyd JA, et al. Opportunities and challenges in ovarian cancer research, a perspective from the 11th ovarian cancer action/HHMT forum, Lake Como, March 2007. Gynecol Oncol. 2008;108:652-7.
3. Wong AS, Leung PC. Role of endocrine and growth factors on the ovarian surface epithelium. J Obstet Gynaecol Res. 2007;33:3-16. (Pubitemid 46028466)
4. Yoshida S, Furukawa N, Haruta S, Tanase Y, Kanayama S, Noguchi T, et al. Expression profiles of genes involved in poor prognosis of epithelial ovarian carcinoma: a review. Int J Gynecol Cancer. 2009;19:992-7.
5. Patterson CE, Gao J, Rooney AP, Davis EC. Genomic organization of mouse and human 65 kDa FK506-binding protein genes and evolution of the FKBP multigene family. Genomics. 2002;79:881-9. (Pubitemid 34595324)
6. Marcen R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs. 2009;69:2227-43.
7. Mukherjee S, Botha JF, Mukherjee U. Immunosuppression in liver transplantation. Curr Drug Targets. 2009;10:557-74.
8. Fraile P, Garcia-Cosmes P, Martin P, Garcia-Bernalt V, Tabernero JM. Non-skin solid tumors as a cause of morbidity and mortality after liver transplantation. Transplant Proc. 2009;41:2433-4.
9. Olesen SH, Christensen LL, Sorensen FB, Cabezon T, Laurberg S, Orntoft TF, et al. Human FK506 binding protein 65 is associated with colorectal cancer. Mol Cell Proteomics. 2005;4:534-44. (Pubitemid 40590570)
10. Alfadhli E, Koh A, Albaker W, Bhargava R, Ackerman T, McDonald C, et al. High prevalence of ovarian cysts in premenopausal women receiving sirolimus and tacrolimus after clinical islet transplantation. Transpl Int. 2009;22:622-5.
11. Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K. Expression and prognostic significance of plateletderived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res. 1993;53:4550-4. (Pubitemid 23304378)
12. Henriksen R, Gobl A, Wilander E, Oberg K, Miyazono K, Funa K. Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGF-beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab Invest. 1995;73:213-20.
13. Henriksen R, Strang P,Wilander E, Backstrom T, Tribukait B, Oberg K. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol. 1994;53:301-6.
14. Armitage BG. Statistical methods in medical research. 2nd ed. Oxford: Blackwell; 1987.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assn. 1958;53:457-81.
16. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-70.
17. Barik S. Immunophilins: for the love of proteins. Cell Mol Life Sci. 2006;63:2889-900. (Pubitemid 46072296)
18. Kang CB, Hong Y, Dhe-Paganon S, Yoon HS. FKBP family proteins: immunophilins with versatile biological functions. Neurosignals. 2008;16:318-25.
19. Patterson CE, Abrams WR, Wolter NE, Rosenbloom J, Davis EC. Developmental regulation and coordinate reexpression of FKBP65 with extracellular matrix proteins after lung injury suggest a specialized function for this endoplasmic reticulum immunophilin. Cell Stress Chaperones. 2005;10:285-95. (Pubitemid 41813377)
20. Ishikawa Y, Vranka J, Wirz J, Nagata K, Bachinger HP. The rough endoplasmic reticulum-resident FK506-binding protein FKBP65 is a molecular chaperone that interacts with collagens. J Biol Chem. 2008;283:31584-90.
21. Shah R, Smith P, Purdie C, Quinlan P, Baker L, Aman P, et al. The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer. Br J Cancer. 2009;100:1687-96.
22. Xue J, Li X, Jiao S, Wei Y, Wu G, Fang J. Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity. Gastroenterology. 2010;138:606-15.
23. Alanay Y, Avaygan H, Camacho N, Utine GE, Boduroglu K, Aktas D, et al. Mutations in the gene encoding the RER protein FKBP65 cause autosomal-recessive osteogenesis imperfecta. Am J Hum Genet. 2010;86:551-9.
24. Godwin AK, Vanderveer L, Schultz DC, Lynch HT, Altomare DA, Buetow KH, et al. A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1. Am J Hum Genet. 1994;55:666-77.
25. Kirken RA, Wang YL. Molecular actions of sirolimus: sirolimus and mTor. Transplant Proc. 2003;35:227S-30S. (Pubitemid 36547948)
26. Seufferlein T, Rozengurt E. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res. 1996;56:3895-7. (Pubitemid 26284735)
27. Giordano A, Romano S, Mallardo M, D'Angelillo A, Cali G, Corcione N, et al. FK506 can activate transforming growth factorbeta signalling in vascular smooth muscle cells and promote proliferation. Cardiovasc Res. 2008;79:519-26.
28. Romano S, Di PA, Sorrentino A, Bisogni R, Sivero L, Romano MF. FK506 binding proteins as targets in anticancer therapy. Anticancer Agents Med Chem. 2010;10:651-6.
29. Donato ML, Levenback C, Gershenson DM, McMeekin S, Champlin RE. Matched unrelated donor bone marrow transplantation for the treatment of platinum refractory ovarian carcinoma: a case report. Gynecol Oncol. 2004;92:365-7. (Pubitemid 38147419)
30. Stippel DL, Kasper HU, Schleimer K, Tox U, Bangard C, Holscher AH, et al. Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. Transplant Proc. 2005;37:2185-7. (Pubitemid 40956407)
31. Chinnakotla S, Davis GL, Vasani S, Kim P, Tomiyama K, Sanchez E, et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver transplant. 2009;15:1834-42.
32. Andersson Y, Engebraaten O, Fodstad O. Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo. Br J Cancer. 2009;101:1307-15.